MedTrace Logo

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

NCT04313166 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2022-02-17

No results posted yet for this study

Summary

Provides up to six months treatment with CuATSM for subjects who have successfully completed study CMD-2019-001

Conditions

Interventions

DRUG

Cu(II)ATSM

cooper-containing synthetic small molecule

Sponsors & Collaborators

  • Collaborative Medicinal Development Pty Limited

    lead INDUSTRY

Principal Investigators

  • Dominic Rowe, MD · Macquarie University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-19
Primary Completion
2021-11-18
Completion
2022-02-15

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04313166 on ClinicalTrials.gov